NO PRODUCT DISCUSSED
Total Payments
$126.4M
Transactions
26,583
Doctors
6,178
Companies
9
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $22.1M | 4,635 | 1,886 |
| 2018 | $56.4M | 11,956 | 3,249 |
| 2017 | $48.0M | 9,992 | 2,247 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $107.4M | 10,473 | 84.9% |
| Consulting Fee | $7.9M | 1,945 | 6.3% |
| Grant | $4.2M | 315 | 3.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.1M | 3,046 | 2.5% |
| Travel and Lodging | $2.2M | 4,569 | 1.7% |
| Charitable Contribution | $768,821 | 244 | 0.6% |
| Food and Beverage | $410,037 | 5,180 | 0.3% |
| Gift | $357,861 | 58 | 0.3% |
| Royalty or License | $34,208 | 4 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $29,700 | 26 | 0.0% |
| Education | $9,061 | 720 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $8,000 | 3 | 0.0% |
Payments by Type
Research
$107.4M
10,473 transactions
General
$19.1M
16,110 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Asthma dupilumab | SANOFI US SERVICES INC. | $6.5M | 6 |
| Diabetes Mellitus | SANOFI US SERVICES INC. | $4.4M | 1 |
| Comparative Effectiveness of Recombinant Influenza Vaccine versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Homes | SANOFI PASTEUR INC. | $4.2M | 0 |
| T2DM SOTA | SANOFI US SERVICES INC. | $4.0M | 5 |
| Insulin glargine / lixisenatid | SANOFI US SERVICES INC. | $3.9M | 4 |
| Asthma Dupilumab | SANOFI US SERVICES INC. | $3.5M | 8 |
| Pomdesar Myeloma | SANOFI US SERVICES INC. | $3.5M | 0 |
| Oncology Anti-CD38 mAb | SANOFI US SERVICES INC. | $3.2M | 0 |
| A Study Evaluating Acute Otitis Media and Nasopharyngeal Colonization Caused by Streptococcus pneumoniae in Healthy Children | SANOFI PASTEUR INC. | $2.8M | 0 |
| bilateral nasal polyposis | SANOFI US SERVICES INC. | $2.7M | 0 |
| INVESTED Study | SANOFI PASTEUR INC. | $2.4M | 0 |
| NEOGAA EFC14028 Local US Costs | SANOFI US SERVICES INC. | $2.3M | 0 |
| Type 2 Diabetes Mellitus | SANOFI US SERVICES INC. | $2.1M | 1 |
| Eff-CVOT | SANOFI US SERVICES INC. | $1.9M | 5 |
| ASMD Pediatric L | SANOFI US SERVICES INC. | $1.7M | 0 |
| REGAIN: Real World and Genomic Data based Asthma Insight through Network Analysis | SANOFI US SERVICES INC. | $1.6M | 0 |
| US Local AED | SANOFI US SERVICES INC. | $1.5M | 1 |
| Rheumatoid Arthritis Sarilumab | SANOFI US SERVICES INC. | $1.4M | 8 |
| Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma | SANOFI US SERVICES INC. | $1.4M | 0 |
| Combo study-GC2008 and alphaPD | SANOFI US SERVICES INC. | $1.2M | 0 |
Top Doctors Receiving Payments for NO PRODUCT DISCUSSED
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Portland, OR | $112.8M | 10,602 |
| , M.D | Cytopathology | Chestnut Hill, MA | $217,342 | 22 |
| , M.D | Allergy | Sarasota, FL | $205,626 | 40 |
| , M.D | Endocrinology, Diabetes & Metabolism | Dallas, TX | $184,145 | 61 |
| , MD | Clinical & Laboratory Immunology | Doylestown, PA | $178,646 | 77 |
| Andrea Leonard-Segal | Rheumatology | Washington, DC | $150,562 | 16 |
| , MD | Specialist | Chattanooga, TN | $149,012 | 11 |
| , M.D | Endocrinology, Diabetes & Metabolism | Rockville, MD | $146,379 | 30 |
| , MD | Hematology & Oncology | Washington, DC | $141,466 | 9 |
| , M.D., F.A.C.P | Endocrinology, Diabetes & Metabolism | Fresno, CA | $138,648 | 18 |
| , MD | Infectious Disease | Baxter, TN | $135,447 | 62 |
| Jeremy Pettus | Endocrinology, Diabetes & Metabolism | San Diego, CA | $129,731 | 57 |
| , M.D | Family Medicine | Gilbert, AZ | $117,284 | 21 |
| , M.D | Internal Medicine | San Diego, CA | $116,087 | 37 |
| , M.D | Endocrinology, Diabetes & Metabolism | Tarzana, CA | $105,908 | 39 |
| , MD | Anesthesiology | Boston, MA | $101,669 | 22 |
| , MD | Internal Medicine | Miami, FL | $97,954 | 22 |
| , MD | Cardiovascular Disease | Kansas City, MO | $95,233 | 28 |
| , M.D | Neurology | Milwaukee, WI | $94,626 | 14 |
| , MD | Endocrinology, Diabetes & Metabolism | Aurora, CO | $89,563 | 32 |
| , M.D | Endocrinology, Diabetes & Metabolism | San Diego, CA | $86,592 | 39 |
| , MD | Allergy & Immunology | Madison, WI | $86,316 | 32 |
| , MD | Pediatrics | Chapel Hill, NC | $86,289 | 67 |
| , MD | Obstetrics & Gynecology | Saint Louis, MO | $83,333 | 1 |
| , D.O | Pediatrics | Yucca Valley, CA | $81,331 | 1 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $82.4M
- SANOFI-AVENTIS U.S. LLC $15.8M
- SANOFI PASTEUR INC. $14.6M
- GENZYME CORPORATION $11.8M
- BIOVERATIV THERAPEUTICS INC. $1.2M
- Sanofi Pasteur Inc. $492,286
- ABLYNX NV $86,144
- VAXSERVE INC. $28,235
- sanofi-aventis U.S. LLC $22,206
Product Information
- Type Drug
- Total Payments $126.4M
- Total Doctors 6,178
- Transactions 26,583
About NO PRODUCT DISCUSSED
NO PRODUCT DISCUSSED is a drug associated with $126.4M in payments to 6,178 healthcare providers, recorded across 26,583 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $22.1M was paid across 4,635 transactions to 1,886 doctors.
The most common payment nature for NO PRODUCT DISCUSSED is "Unspecified" ($107.4M, 84.9% of total).
NO PRODUCT DISCUSSED is associated with 20 research studies, including "Asthma dupilumab" ($6.5M).